Predict your next investment

CUORiPS company logo
HEALTHCARE | Biotechnology
cuorips.co.jp

See what CB Insights has to offer

Founded Year

2017

Stage

Series C | Alive

Total Raised

$42.95M

Last Raised

$14.73M | 5 mos ago

About CUORiPS

CUORiPS is a developer of cell therapy products. The company develops allogeneic iPSC-derived cardiomyocyte sheets for the treatment of heart failure. It aims to enable transplantation of the sheets for patients with severe deficiencies in their heart function.

CUORiPS Headquarter Location

507, Nihonbashi Life Science Building 2 3-11-5 Nihonbashi Honcho, Chuo-ku

Tokyo, 103-0023,

Japan

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CUORiPS

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

CUORiPS is included in 2 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,708 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharmaceuticals

5,731 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.